GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Merck & Co Inc (BUE:MRK) » Definitions » EV-to-EBITDA

Merck (BUE:MRK) EV-to-EBITDA

: 141.45 (As of Today)
View and export this data going back to . Start your Free Trial

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Merck's enterprise value is ARS300,044,610 Mil. Merck's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was ARS2,121,247 Mil. Therefore, Merck's EV-to-EBITDA for today is 141.45.

The historical rank and industry rank for Merck's EV-to-EBITDA or its related term are showing as below:

BUE:MRK' s EV-to-EBITDA Range Over the Past 10 Years
Min: 6.41   Med: 14.11   Max: 52.6
Current: 49.97

During the past 13 years, the highest EV-to-EBITDA of Merck was 52.60. The lowest was 6.41. And the median was 14.11.

BUE:MRK's EV-to-EBITDA is ranked worse than
91.93% of 706 companies
in the Drug Manufacturers industry
Industry Median: 13.805 vs BUE:MRK: 49.97

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-04-19), Merck's stock price is ARS26649.00. Merck's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was ARS1329.075. Therefore, Merck's PE Ratio for today is 20.05.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Merck EV-to-EBITDA Historical Data

The historical data trend for Merck's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Merck Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 20.77 21.73 12.22 14.03 44.02

Merck Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-EBITDA Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 14.03 14.54 31.87 23.31 44.02

Competitive Comparison

For the Drug Manufacturers - General subindustry, Merck's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Merck EV-to-EBITDA Distribution

For the Drug Manufacturers industry and Healthcare sector, Merck's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Merck's EV-to-EBITDA falls into.



Merck EV-to-EBITDA Calculation

Merck's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=300044610.291/2121247.197
=141.45

Merck's current Enterprise Value is ARS300,044,610 Mil.
Merck's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ARS2,121,247 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Merck  (BUE:MRK) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Merck's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=26649.00/1329.075
=20.05

Merck's share price for today is ARS26649.00.
Merck's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ARS1329.075.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Merck EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Merck's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Merck (BUE:MRK) Business Description

Address
126 East Lincoln Avenue, Rahway, NJ, USA, 07065
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.

Merck (BUE:MRK) Headlines

From GuruFocus

Merck & Co Inc Annual Shareholders Meeting Transcript

By GuruFocus Research 01-23-2024

Q3 2022 Merck & Co Inc Earnings Call Transcript

By GuruFocus Research 01-23-2024

Q2 2022 Merck & Co Inc Earnings Call Transcript

By GuruFocus Research 01-23-2024

Q1 2023 Merck & Co Inc Earnings Call Transcript

By GuruFocus Research 01-23-2024

Q3 2023 Merck & Co Inc Earnings Call Transcript

By GuruFocus Research 01-23-2024

Merck Announces Second-Quarter 2024 Dividend

By Business Wire 01-23-2024

Merck & Co Inc Investor Event at ACC.23/WCC Transcript

By GuruFocus Research 01-23-2024